Latest News and Press Releases

APOLLO BEACH, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today a new laboratory lease agreement with life...

RetinalGenix Technologies to Participate at 2025 Roth Conference and will discuss patented remote monitoring high-resolution retinal imaging and biomarkers

RETINALGENIX TECHNOLOGIES BREAKTHROUGH IN REAL-TIME 24/7 REMOTE OCULAR MONITORING High-Resolution Retinal Imaging Using Both Near Infrared And Green Modes

RetinalGeniX Granted A New Patent for an Affordable and Effective Device and Method To Detect Ocular And Systemic Diseases

RETINALGENIX AND MEDSAN CONTRACT TO ADVANCE STUDY INTENDED TO PERSONALIZE MEDICAL EVALUATIONS FOR PATIENTS RECEIVING TREATMENT FOR WET MACULAR DEGENERATION

RETINALGENIX TECHNOLOGIES INC. APPOINTS ANATOLY DRITSCHILO, M.D. TO THE COMPANY’S MEDICAL ADVISORY BOARD

RETINALGENIX TECHNOLOGIES INC. APPOINTS DESSY BONEVA, MD, FACS TO THE BOARD OF DIRECTORS Dr. Boneva is an experienced surgeon skilled in trauma, surgical

RETINALGENIX TECHNOLOGIES INC. ANNOUNCES HIRING OF INTERIM CFO Virender Ahluwalia will serve as Interim Chief Financial Officer

RETINALGENIX TECHNOLOGIES INC. APPOINTS STEPHEN TANNENBAUM TO THE COMPANY'S BUSINESS ADVISORY BOARD. RetinalGeniX is an ophthalmic R&D company

RetinalGeniX Announces Therapeutic Solutions Being Developed for Dry Age-Related Macular Degeneration and Alzheimer’s Syndrome.